Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR5A | P47898 | 14/20 | 0.44 |
| ▸ | SLC9A1 | P19634 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9907808 | 0.93 | HTR5A (0.45) | HTR5ASLC9A1 | |
| SCHEMBL12875038 | 0.86 | ITGB3 (0.35) | HTR5ASLC9A1 | |
| SCHEMBL9909222 | 0.84 | HTR5A (0.52) | HTR5AMAPK1 | |
| SCHEMBL9907807 | 0.84 | HTR5A (0.47) | HTR5AMAPK1 | |
| SCHEMBL9909215 | 0.83 | RXRA (0.52) | MAPK1 | |
| SCHEMBL9909300 | 0.83 | HTR5A (0.46) | HTR5ASLC9A1 | |
| SCHEMBL9909290 | 0.83 | HTR5A (0.46) | HTR5A | |
| SCHEMBL9907787 | 0.82 | PIK3CA (0.49) | HTR5ASLC9A1 | |
| SCHEMBL9909187 | 0.79 | HTT (0.46) | — | |
| SCHEMBL9909229 | 0.78 | HTR5A (0.46) | HTR5ASLC9A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853242-B2 | Nitrogenous-ring acylguanidine derivative | ASTELLAS PHARMA INC. (JP) | 2014-10-07 | — | — | US | disclosed |
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | HTR5A 1/4885SLC9A1 1181/4885MAPK1 3555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.